Stockreport

Arcutis Biotherapeutics (ARQT) Valuation Check After New Pediatric ZORYVE Phase 3 Extension Data [Yahoo! Finance]

Arcutis Biotherapeutics, Inc. - Common stock  (ARQT) 
PDF Arcutis Biotherapeutics (ARQT) is back in focus after new Phase 3 extension data for its ZORYVE cream 0.05% in young children with mild-to-moderate atopic dermatitis wa [Read more]